Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Advanced Squamous Cell Lung Carcinoma Patients with Sensitive EGFR Mutations

Objective To investigate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) for advanced squamous cell lung carcinoma patients with sensitive EGFR mutations. Methods We retrospectively analyzed 20 patients with advanced or recurrent SCC harboring EGFR mutation who were treated with EGFR-TKIs in West China Hospital Sichuan University to investigate the efficacy. Results The data of 20 EGFR-mutant squamous cell lung carcinoma patients received EGFR-TKIs was sufficient. Among them, 10 patients had exon 19 deletions, 8 patients had L858R point mutations in exon 21, 1 patient had coexisted L858R and T790M mutation in exon 21, and 1 patient had G719X in exon 18. In the 20 patients, the response to EGFR-TKIs included 9 PR, 7 SD and 4 PD. The response rate was 45% and the disease control rate was 80%. The median progression-free survival(mPFS) and median overall survival(mOS) was 5.0 and 14.7 months, respectively. Conclusion Some EGFR-mutated squamous cell lung carcinoma patients could response to EGFR-TKIs. To better identify these patients, EGFR mutation status should be take into consideration.